#MoST Our brilliant bio- and clinical informaticians: Frank Lin, John Grady and Subo Thavaneswaran! Working on matching the right patients to the right trials around the country. 13,000 lines of code and counting...Garvan Institute of Medical Research Rare Cancers Australia

No. 4 pan-cancer approvals: a game-changer for up to 10% of all cancer patients, esp. rare and less common. FDA Approves Pembrolizumab for TMB-High Tumors onclive.com/view/fda-appro… via OncLive.com Omico Australia Rare Cancers Australia The Kinghorn Cancer Centre Garvan Institute of Medical Research

#ASPiRATIONstudy identifies more actionable mutations than standard of care testing & is optimal workup strategy for Aus newly diag non-sq mNSCLC patients rb.gy/ff6v6c Refer from any site rb.gy/gjaxu6 Omico Australia NHMRC CTC #LCSM

#cholangiocarcinoma: better real-world outcomes are seen in patients who received genomic matched drugs in the MoST study. Time to treat CCa like lung ca. Trials/drug access must improve. #AGITG22 Subo #Precision Omico Australia NHMRC CTC

Our Superstar Subo gave a great argument supporting that precision medicine is NOT past its use by date NECTA drug development meeting’s debate today!